This would be a problem for registration of bisantrene, but it is not a problem from a practical perspective. Any oncologist wanting to use bisantrene off-label in AML would look at the overall results and use the best combination. Let’s say we are lucky and we can get 60% of these patients bridged to a transplant, then this is what the oncologists want to know and be able to tell their patients. While we might not know exactly how much bisantrene is adding to the success of the combination, the oncologist will know the overall response rate and the side effects to expect from the combination.
- Forums
- ASX - By Stock
- RAC
- Ann: First Patient Dosed in Phase 1b/2 AML Trial
Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-34
-
-
- There are more pages in this discussion • 212 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M |
Open | High | Low | Value | Volume |
$1.95 | $1.95 | $1.84 | $647.3K | 344.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3300 | $1.87 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.94 | 5654 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3300 | 1.870 |
4 | 46789 | 1.840 |
2 | 6500 | 1.830 |
2 | 649 | 1.820 |
1 | 829 | 1.805 |
Price($) | Vol. | No. |
---|---|---|
1.940 | 5654 | 2 |
1.950 | 7570 | 1 |
1.960 | 1350 | 1 |
1.990 | 4701 | 2 |
1.995 | 10037 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online